Camizestrant improves tumor control in D538G ESR1m and N354K PIK3CAm PDX CTC174 in combination with CDK4/6 or PI3K/AKT/mTOR inhibitors ex vivo and in vivo. Here, CDK4 is linked to neoplasm.